Bios Partners related stories
All articles and analysis
Bios Partners targets $50 mln second fundBios Partners in Fort Worth, Texas, has filed to raise a $50 million second fund, according to a regulatory filing https://www.sec.gov/Archives/edgar/data/1728851/000172885118000001/xslFormDX01/primary_doc.xml The filing for Bios Fund II NT lists Leslie Kries, Jr. and Aaron Fletcher as managing partners.
- VC-backed Azitra taps Andrews as president and CEO
Azitra, which is backed by Bios Partners and Breakout Labs, has named Richard Andrews as president and CEO. Previously, Andrews was CEO of Thrasos Therapeutics. Based in Farmington, Connecticut, Azitra is a focused on treating skin disease via microbiome.
- Lung Therapeutics gathers $14.3 mln Series B
Austin, Texas-based Lung Therapeutics Inc, a clinical stage pharmaceutical company, has closed $14.3 million in Series B financing. Bios Partners led the round with participation from return backer, the UT Horizon Fund.
- Lantern Pharma rallies $3.7 mln Series A
Lantern Pharma Inc, a clinical-stage biotech company, has raised $3.7 million in Series A financing. The investors included Bios Partners and GPG Ventures.
- 410 Medical nets $3.3 mln Series A
Durham, North Carolina-based 410 Medical Inc, a medical device company focused on developing technologies for critically ill patients, has raised $3.3 million in Series A funding. Bios Partners led the round.